Taysha Gene Therapies TSHA Cash Flow Statement (2019-2026)

NASDAQ TSHA
$5.61 +0.04 (+0.72%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Taysha Gene Therapies Quarterly Cash Flow Statement

Periods 27 quarters
Latest Jun 2026

Taysha Gene Therapies reported cash from operations of -$40.42M and free cash flow of -$40.78M for the quarter ended Jun 2026, down 100.3% year over year. This cash flow statement covers 27 quarters of results from Dec 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-51.19M-50.39M-50.31M-34.09M-26.53M-55.07M-17.61M-24.60M-16.61M-15.04M-22.67M-19.89M-23.82M-18.25M-20.11M-24.91M-30.87M-25.44M-40.91M-45.03M
Share-based Compensation
5.09M4.96M5.44M5.15M4.55M4.10M5.23M2.41M2.57M1.97M4.53M3.40M3.36M3.22M4.71M3.46M23.59M3.53M5.55M5.81M
Gains from Investment Securities
-65.74M0.34M-0.20M-0.07M-0.08M-0.10M0.27M0.29M0.74M
Asset Writedowns and Impairment
0.62M0.45M4.84M
Cash from Operations
-31.93M-40.26M-40.94M-33.35M-28.81M14.71M-20.18M-18.77M-17.95M-16.12M-19.80M-21.50M-21.61M-18.31M-22.02M-20.18M-24.17M-26.72M-40.88M-40.42M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.31M0.34M0.39M0.28M0.30M0.30M0.30M0.27M0.33M0.29M0.30M0.30M0.34M0.31M0.31M0.40M0.28M0.27M
Change in Working Capital
Change in Account Payables
13.62M-1.51M2.54M3.67M-9.43M-4.59M0.36M1.76M-3.19M-1.23M3.98M-1.61M-3.78M-1.50M0.92M3.00M-1.95M-2.13M1.29M4.56M
Change in Accured Expenses
-2.87M5.36M-0.78M-7.68M-0.12M-0.75M-0.25M-1.07M-2.94M-2.02M0.42M-2.38M0.43M0.11M-2.12M0.73M5.01M2.67M-5.15M0.86M
Other Working Capital Changes
-1.75M1.83M-0.27M0.19M-1.90M-0.11M0.40M-0.91M-3.50M-2.00M0.69M-0.82M0.74M-0.82M1.05M-0.48M-0.97M2.13M0.79M0.65M
Investing Activities
Capital Expenditures
3.50M8.27M8.43M7.86M2.02M2.31M3.90M-0.05M0.02M0.14M0.30M-0.07M-0.00M0.38M0.03M0.08M0.25M0.02M0.35M
Cash from Investing Activities
-4.00M-8.52M-11.43M-8.11M-3.02M-2.37M-3.90M0.05M-3.49M-0.01M-0.14M-0.20M-0.04M0.01M-0.37M0.06M-0.05M-0.25M-3.02M0.00M
Financing Activities
Other financing activities
0.28M-1.04M0.06M-0.33M0.05M-0.21M-0.10M74.59M-0.03M-0.01M-0.17M0.04M-0.08M0.15M-0.32M1.88M0.52M0.44M
Debt Issuance and Repayment
Long-Term Debt Issuances
10.00M
Change in Capital Stock
Net Shares Issued and Repurchased
0.42M3.19M1.90M0.78M4.78M1.77M1.43M0.05M1.52M7.80M1.42M1.38M11.72M7.44M1.72M0.34M11.01M2.67M0.73M
Net Equity Issued and Repurchased
0.04M16.08M
Misc.
Cash from Financing Activities
9.11M-0.11M11.07M-0.10M41.23M-0.37M0.38M140.63M-4.25M-0.02M70.47M6.59M-0.36M-0.05M216.29M8.80M49.56M0.71M216.66M
Change in Cash
-5.96M-39.67M-52.47M-30.39M-31.93M53.57M-24.45M-18.34M119.19M-20.38M-19.96M48.76M-15.05M-18.65M-22.44M196.17M-15.42M22.59M-43.19M176.23M
Free Cash Flow
-35.44M-48.53M-49.37M-41.22M-30.83M12.40M-24.09M-18.72M-17.95M-16.13M-19.94M-21.81M-21.55M-18.31M-22.40M-20.21M-24.24M-26.97M-40.90M-40.78M
Net Cash Flow
-35.94M-39.67M-52.47M-30.39M-31.93M53.57M-24.45M-18.34M119.19M-20.38M-19.96M48.76M-15.05M-18.65M-22.44M196.17M-15.42M22.59M-43.19M176.23M